Nath Bio-Genes (India) share news, announcements and annual reports
NSE: NATHBIOGENBSE: 537291Agricultural Food & other ProductsSmall Cap
Nath Bio-Genes (India) Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jan 2014
Last close ₹131.01down ₹1.37 (1.03%)BSE ₹131.50
Share price at the NSE close on 30 Oct 2026. Previous close ₹132.38.
30 Oct: open ₹132.05, high ₹135.95, low ₹130.52
52-week range of traded prices to 30 Oct 2026
₹126.15Low, 30 Mar 2026₹204.00High, 30 Apr 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹249 Cr2,134th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 6.80
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes ₹7.21 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 8.47
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 0.37
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 1.53%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 5.5%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes ₹7.21 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 4.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 5.5%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.20
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 5,41466.2% delivered
Nath Bio-Genes (India) disputes and clarifications
24 filed, newest first.
Sep 2026
9 Sep · Legal
Exchange has sought clarification from Nath Bio-Genes (India) Limited for the quarter ended 30-Jun-2026 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: The response of the Company is awaited.
Sep 2025
4 Sep · Legal
Exchange has sought clarification from Nath Bio-Genes (India) Limited for the quarter ended 30-Jun-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted in XBRL with discrepancies The response of the Company is awaited.
Aug 2024
19 Aug · Legal
Exchange has sought clarification from Nath Bio-Genes (India) Limited for the quarter ended 30-Jun-2024 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.
May 2023
Apr 2023
26 Apr · Legal
Exchange has sought clarification from Nath Bio-Genes (India) Limited for the quarter ended 31-Mar-2023 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.
Jun 2021
2 Jun · Legal
The exchange asked on 1 Jun 2021
May 2021
18 May · Legal
The exchange asked on 17 May 2021
May 2020
6 May · Legal
Exchange has sought clarification from Nath Bio-Genes (India) Limited with respect to announcement dated 28-Apr-2020 regarding Introduction of New Cotton Hybrids. On basis of above the Company is required to clarify following: 1. Date of launch;2. Category of the product;3. Whether caters to domestic/ international market;4. Name of the countries in which the product is launched (in case of international).The response of the Company is awaited.
Apr 2020
17 Apr · Legal
The exchange asked on 13 Apr 2020
Mar 2020
14 Mar · Legal
The exchange asked on 13 Mar 2020
May 2019
Apr 2019
22 Apr · Legal
Exchange has sought clarification from Nath Bio-Genes (India) Limited with respect to announcement dated 11-Apr-2019, regarding retirement. On basis of above you are required to clarify following -1. Date of appointment/cessation (as applicable) & term of appointment.The response of the Company is awaited.
Aug 2018
1 Aug · Legal
Exchange has sought clarification from Nath Bio-Genes (India) Limited with respect to announcement dated 31-Jul-2018, regarding " Nath Bio-Genes (India) Limited has informed the Exchange regarding Outcome of Board Meeting held on July 31, 2018.". On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment); The response of the Company is awaited.
Jun 2018
27 Jun · Legal
Exchange has sought clarification from Nath Bio-Genes (India) Limited with respect to announcement dated 27-Jun-2018, regarding " Nath Bio-Genes (India) Limited has informed the Exchange regarding Management Enhancement.". On basis of above the Company is required to clarify following: 1. Date of appointment/cessation (as applicable) & term of appointment; The response of the Company is awaited.1 Jun · Legal
Exchange has sought clarification from Nath Bio-Genes (India) Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Standalone Reconciliation of profit and loss not submitted -2. Standalone Reconciliation of Equity not submitted The response of the Company is awaited.
Apr 2018
6 Apr · Legal
The exchange asked on 5 Apr 2018
Mar 2018
Feb 2018
15 Feb · Legal
Exchange has sought clarification from Nath Bio-Genes (India) Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Reconciliation of profit and loss not submitted. The response of the Company is awaited.
Jan 2018
8 Jan · Legal
The exchange asked on 3 Jan 2018
Nov 2017
2 Nov · Legal
Exchange has sought clarification from Nath Bio-Genes (India) Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results not submitted as per Schedule III to the Companies Act, 2013 -2. Financial results not submitted as per Ind-AS format -3. Reconciliation of profit and loss not submitted The response of the Company is awaited.
Jul 2017